Graham Capital Management, L.P. Dyne Therapeutics, Inc. Transaction History
Graham Capital Management, L.P.
- $3.11 Billion
- Q2 2024
A detailed history of Graham Capital Management, L.P. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 6,618 shares of DYN stock, worth $227,262. This represents 0.01% of its overall portfolio holdings.
Number of Shares
6,618
Previous 18,396
64.02%
Holding current value
$227,262
Previous $522,000
55.36%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding DYN
# of Institutions
201Shares Held
106MCall Options Held
82.7KPut Options Held
24.8K-
Atlas Venture Life Science Advisors, LLC8.02MShares$275 Million37.7% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$269 Million40.83% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$254 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.39MShares$219 Million3.76% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$208 Million3.22% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.78B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...